← All trials
NCT00997035
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2010
- Primary completion
- Jan 1, 2016
- Completion date
- Mar 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, San FranciscoLead sponsor
- National Eye Institute (NEI)Collaborator
- Dartmouth UniversityCollaborator
- University of California, San FranciscoOverall official - principal investigator
- Lumbini Eye Institute and HospitalCollaborator
- Bharatpur Eye Hospital, NepalCollaborator
- Aravind Eye HospitalCollaborator
- University of California, San FranciscoReponsible party - principal investigator
- Aravind Eye HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.